Search
Personalis Inc
PSNLAdd to Watchlist
13.565USD
-0.225-1.63%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.20BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-01The current earnings forecast score of Personalis Inc is 8.29, ranking 141 out of 387 in the Biotechnology & Medical Research industry. The average price target is 11.00, with a high of 12.00 and a low of 10.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
10.857
Target Price
-18.98%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Personalis Inc
PSNL
7
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Personalis Inc's expected revenue for the next quarter?
Personalis Inc's expected revenue is 16.83M.
What is Personalis Inc's price target?
Analysts forecast that Personalis Inc's price target is USD 11.00, with the highest forecast at USD 12.00 and the lowest forecast at USD 10.00.
How have Personalis IncPSNL's recent earnings per share performed?
The market expectation was USD -0.29, while Personalis IncPSNL's earnings per share (EPS) for the previous quarter was USD -0.26. EPS for the next quarter is expected at USD -0.26.
What is the analyst rating for Personalis Inc?
Based on the ratings of Personalis Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.